Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 4
2021 5
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E, Kowall B, Hassel JC, Schilling B, Sachse M, Gutzmer R, Loquai C, Kähler KC, Hüsing A, Gilde C, Thielmann CM, Zaremba-Montenari A, Placke JM, Gratsias E, Martaki A, Roesch A, Ugurel S, Schadendorf D, Livingstone E, Stang A, Zimmer L. Chorti E, et al. Eur J Cancer. 2024 Mar;200:113536. doi: 10.1016/j.ejca.2024.113536. Epub 2024 Jan 18. Eur J Cancer. 2024. PMID: 38306840 Free article.
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E, Kebir S, Ahmed MS, Keyvani K, Umutlu L, Kanaki T, Zaremba A, Reinboldt-Jockenhoefer F, Knispel S, Gratsias E, Roesch A, Ugurel S, Scheffler B, Schadendorf D, Livingstone E, Meier F, Glas M, Zimmer L. Chorti E, et al. Eur J Cancer. 2021 May;148:395-404. doi: 10.1016/j.ejca.2021.02.016. Epub 2021 Mar 28. Eur J Cancer. 2021. PMID: 33789203
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology.
Zaremba A, Lodde G, Murali R, Philip M, Cosgarea I, Jansen P, Chorti E, Rose C, Hemmerlein B, Matull J, Thielmann CM, Kretz J, Möller I, Sucker A, Paschen A, Livingstone E, Zimmer L, Horn S, Schadendorf D, Hadaschik E, Griewank K. Zaremba A, et al. Among authors: chorti e. Eur J Cancer. 2021 May;148:340-347. doi: 10.1016/j.ejca.2021.02.025. Epub 2021 Mar 25. Eur J Cancer. 2021. PMID: 33773277 Free PMC article.
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
Ferdinandus J, Zaremba A, Zimmer L, Umutlu L, Seifert R, Barbato F, Ugurel S, Chorti E, Grünwald V, Herrmann K, Schadendorf D, Fendler WP, Livingstone E. Ferdinandus J, et al. Among authors: chorti e. Cancer Imaging. 2022 Feb 5;22(1):11. doi: 10.1186/s40644-022-00449-3. Cancer Imaging. 2022. PMID: 35123578 Free PMC article.
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival.
Thielmann CM, Matull J, Roth S, Placke JM, Chorti E, Zaremba A, Lodde G, Jansen P, Krefting F, Kretz J, Möller I, Sucker A, Paschen A, Livingstone E, Zimmer L, Ugurel S, Schadendorf D, Hadaschik E, Griewank KG. Thielmann CM, et al. Among authors: chorti e. Cancers (Basel). 2022 Apr 22;14(9):2090. doi: 10.3390/cancers14092090. Cancers (Basel). 2022. PMID: 35565222 Free PMC article.
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM, Matull J, Zaremba A, Murali R, Chorti E, Lodde G, Jansen P, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Kretz J, Möller I, Sucker A, Paschen A, Livingstone E, Zimmer L, Hadaschik E, Ugurel S, Schadendorf D, Griewank KG. Thielmann CM, et al. Among authors: chorti e. Eur J Cancer. 2022 Jan;161:99-107. doi: 10.1016/j.ejca.2021.11.009. Epub 2021 Dec 20. Eur J Cancer. 2022. PMID: 34936949 Free PMC article.
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM, Chorti E, Matull J, Murali R, Zaremba A, Lodde G, Jansen P, Richter L, Kretz J, Möller I, Sucker A, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Paschen A, Livingstone E, Zimmer L, Schadendorf D, Hadaschik E, Ugurel S, Griewank KG. Thielmann CM, et al. Among authors: chorti e. Eur J Cancer. 2021 Dec;159:113-124. doi: 10.1016/j.ejca.2021.09.035. Epub 2021 Nov 4. Eur J Cancer. 2021. PMID: 34742158 Free PMC article.
15 results